Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
zivo bioscience, inc., a u.s.-based r&d firm, is dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains.Zivo Bioscience, Inc. reported insider information for its Chief Financial Officer, William A. Sullivan, in a Form 3 initial ownership filing. The filing shows that as of the event date of 12/19/2025, he reported beneficial ownership of 0 shares of Zivo Bioscience, Inc. common stock and no derivative securities such as options or warrants. The form is filed as an individual reporting person and confirms that he currently holds no direct or indirect equity or derivative position in the company.
Zivo Bioscience, Inc. reported that Chief Financial Officer Keith R. Marchiando has resigned from his CFO role effective immediately and will end his employment on December 31, 2025. Under a separation and release agreement, he will continue to receive his current salary of $27,040 per month through December 31, 2026, and will retain an option to acquire 150,000 shares of common stock at an exercise price of $7.96 per share, exercisable until June 30, 2027.
The company appointed William A. Sullivan as Interim Chief Financial Officer effective December 19, 2026, under an independent contractor services agreement. He will be paid $285.00 per hour for his work, with an initial 60-day term that automatically renews for one-month periods unless either party provides notice. Mr. Sullivan is subject to confidentiality and post-termination restrictions aimed at protecting the company’s business relationships.
Zivo Bioscience, Inc. director and 10% owner reported buying additional company shares. On 11/28/2025, an indirect account, HEP Investments LLC, purchased 2,777 shares of Zivo Bioscience common stock at a price of $9 per share. After this transaction, the reporting person beneficially owned 577,872 shares of common stock indirectly through HEP Investments LLC.
ZIVO Bioscience (ZIVO) filed its Q3 2025 10‑Q, showing modest revenue growth alongside tight liquidity and continued losses. Revenue was $65,625, up from $31,500, with gross margin of $21,288. The company reported a net loss of $1,033,056 for the quarter and operating cash outflow of $2,173,204 for the nine months.
Cash declined to $57,222 with total liabilities of $3,846,055 and a stockholders’ deficit of $(3,286,603). Shares outstanding were 3,832,327 as of September 30, 2025, and 3,888,595 as of November 9, 2025. Management states there is substantial doubt about the ability to continue as a going concern and estimates needing about $6.0 million over the next 12 months to fund basic operations.
During 2025, ZIVO raised funds via private equity and debt, including a $250,000 convertible note at 10% with warrants to purchase 1,793 shares at $13.94. Subsequent to quarter‑end (October 2025), the company sold 54,168 shares and 3,091 warrants, raising $390,000 in cash and exchanging $284,433 of related party payables. Material weaknesses in internal control over financial reporting persist.
FAQ
What is the current stock price of Zivo Bioscience (ZIVOW)?
